| Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline DL Hershman, C Lacchetti, RH Dworkin, EM Lavoie Smith, J Bleeker, ... J Clin Oncol 32 (18), 1941-1967, 2014 | 1397 | 2014 |
| Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with … BP Schneider, M Wang, M Radovich, GW Sledge, S Badve, A Thor, ... Journal of Clinical Oncology 26 (28), 4672, 2008 | 722 | 2008 |
| Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update CL Loprinzi, C Lacchetti, J Bleeker, G Cavaletti, C Chauhan, DL Hertz, ... Journal of Clinical Oncology 38 (28), 3325-3348, 2020 | 602 | 2020 |
| Angiogenesis of breast cancer BP MILLER, KD SCHNEIDER JOURNAL OF CLINICAL ONCOLOGY 23 (8), 1782-1790, 2005 | 494 | 2005 |
| Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2–positive breast cancer SM Tolaney, H Guo, S Pernas, WT Barry, DA Dillon, L Ritterhouse, ... Journal of Clinical Oncology 37 (22), 1868, 2019 | 282 | 2019 |
| Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years AJ Tevaarwerk, RJ Gray, BP Schneider, ML Smith, LI Wagner, JH Fetting, ... Cancer 119 (6), 1140-1148, 2013 | 241 | 2013 |
| Advanced cognitive training for breast cancer survivors: a randomized controlled trial D Von Ah, JS Carpenter, A Saykin, P Monahan, J Wu, M Yu, G Rebok, ... Breast cancer research and treatment 135, 799-809, 2012 | 235 | 2012 |
| Association of circulating tumor DNA and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in patients with triple-negative breast cancer … M Radovich, G Jiang, BA Hancock, C Chitambar, R Nanda, C Falkson, ... JAMA oncology 6 (9), 1410-1415, 2020 | 202 | 2020 |
| Association of polymorphisms of angiogenesis genes with breast cancer BP Schneider, M Radovich, GW Sledge, JD Robarge, L Li, AM Storniolo, ... Breast cancer research and treatment 111, 157-163, 2008 | 162 | 2008 |
| Drug insight: VEGF as a therapeutic target for breast cancer BP Schneider, GW Sledge Jr Nature clinical practice Oncology 4 (3), 181-189, 2007 | 145 | 2007 |
| Genome-wide association studies for taxane-induced peripheral neuropathy in ECOG-5103 and ECOG-1199 BP Schneider, L Li, M Radovich, F Shen, KD Miller, DA Flockhart, G Jiang, ... Clinical Cancer Research 21 (22), 5082-5091, 2015 | 143 | 2015 |
| A 25-year single institution experience with surgery for primary mediastinal nonseminomatous germ cell tumors KA Kesler, KM Rieger, ZT Hammoud, LE Kruter, SM Perkins, ... The Annals of thoracic surgery 85 (2), 371-378, 2008 | 126 | 2008 |
| Phase III trial evaluating letrozole as first-line endocrine therapy with or without bevacizumab for the treatment of postmenopausal women with hormone receptor–positive … MN Dickler, WT Barry, CT Cirrincione, MJ Ellis, ME Moynahan, F Innocenti, ... Journal of Clinical Oncology 34 (22), 2602, 2016 | 121 | 2016 |
| Cancer-associated alteration of pericentromeric heterochromatin may contribute to chromosome instability RB Slee, CM Steiner, BS Herbert, GH Vance, RJ Hickey, T Schwarz, ... Oncogene 31 (27), 3244-3253, 2012 | 115 | 2012 |
| NCCN Guidelines® Insights: Breast Cancer, Version 4.2023: Featured Updates to the NCCN Guidelines WJ Gradishar, MS Moran, J Abraham, V Abramson, R Aft, D Agnese, ... Journal of the National Comprehensive Cancer Network 21 (6), 594-608, 2023 | 114 | 2023 |
| Acceptance and commitment therapy for symptom interference in metastatic breast cancer patients: a pilot randomized trial CE Mosher, E Secinti, R Li, AT Hirsh, J Bricker, KD Miller, B Schneider, ... Supportive Care in Cancer 26, 1993-2004, 2018 | 114 | 2018 |
| The role of vascular endothelial growth factor genetic variability in cancer BP Schneider, M Radovich, KD Miller Clinical Cancer Research 15 (17), 5297-5302, 2009 | 113 | 2009 |
| Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): a randomized clinical trial SM Tolaney, N Tayob, C Dang, DA Yardley, SJ Isakoff, V Valero, ... Journal of Clinical Oncology 39 (21), 2375-2385, 2021 | 109 | 2021 |
| Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer BP Schneider, F Zhao, M Wang, V Stearns, S Martino, V Jones, EA Perez, ... Journal of clinical oncology 30 (25), 3051, 2012 | 105 | 2012 |
| Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants V Stearns, B Schneider, NL Henry, DF Hayes, DA Flockhart Nature Reviews Cancer 6 (11), 886-893, 2006 | 99 | 2006 |
